Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Mitoxantrone With or Without Docetaxel in Treating Women With Metastatic Breast Cancer

This study has been completed.
Sponsor:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00002544
First received: November 1, 1999
Last updated: August 1, 2013
Last verified: April 2001

November 1, 1999
August 1, 2013
May 1993
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00002544 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Mitoxantrone With or Without Docetaxel in Treating Women With Metastatic Breast Cancer
MITOXANTRONE (N) VS. 5-FLUOROURACIL, EPIRUBICIN AND CYCLOPHOSPHAMIDE AS FIRST-LINE CHEMOTHERAPY FOR PATIENTS WITH METASTATIC BREAST CANCER AND AN UNFAVORABLE PROGNOSIS

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if mitoxantrone is more effective with or without docetaxel.

PURPOSE: Randomized phase III trial to compare the effectiveness of mitoxantrone with or without docetaxel in treating women who have metastatic breast cancer with a poor prognosis.

OBJECTIVES:

  • Compare the survival and quality of life scores (composed of time to progression, WHO performance status, subjective patient evaluation, and subjective adverse event profile) among women with metastatic breast cancer of unfavorable prognosis treated with mitoxantrone vs mitoxantrone plus docetaxel as first-line chemotherapy for metastatic disease.
  • Compare the remission rate, time to remission, remission duration, time to best response, objective adverse events, and patient acceptance of treatment on these 2 regimens.
  • Investigate which prognostic subgroups of women benefit from treatment.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to age, treatment center, disease free interval (no more than 18 months vs more than 18 months), hormone receptor status (positive or unknown vs negative), prior adjuvant therapy with anthracyclines (yes vs no), presence of liver metastases (liver involvement as a single organ vs liver plus other organ involvement vs no liver involvement), and presence of lung metastases (yes vs no). Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive mitoxantrone IV on day 1. Treatment repeats every 3 weeks until disease progression, unacceptable toxicity, or maximum cumulative dose. Patients who achieve complete response receive 2 additional courses.
  • Arm II: Patients receive mitoxantrone IV plus docetaxel IV over 1 hour on day 1. Treatment repeats every 3 weeks for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity.

At relapse, reinduction with the original regimen is attempted. Following a second complete response, 2 additional courses of consolidative treatment are given, and patients are then followed off treatment.

Quality of life is assessed periodically.

PROJECTED ACCRUAL: A total of 300 patients will be accrued for this study.

Interventional
Phase 3
Allocation: Randomized
Primary Purpose: Treatment
Breast Cancer
  • Drug: docetaxel
  • Drug: mitoxantrone hydrochloride
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
300
November 2002
Not Provided

DISEASE CHARACTERISTICS:

  • Histologically proven metastatic breast cancer of poor prognosis, defined by any of the following characteristics:

    • Patient aged 35 or under
    • Liver metastases
    • Lung metastases combined with other disease manifestations
    • Lung metastases without other disease manifestations but with a disease free interval of no more than 18 months
  • Indication for chemotherapy documented by either:

    • Hormone receptor negativity OR
    • Hormone resistant disease
  • Measurable metastatic disease required

    • Nonmeasurable disease includes:

      • Metastases verified only histologically
      • Tumor parameters not precisely measurable (e.g., bone marrow involvement, lymphangitic disease)
  • No CNS metastasis or bone marrow carcinomatosis
  • Hormone receptor status:

    • Receptor status known

PATIENT CHARACTERISTICS:

Age:

  • 80 and under

Sex:

  • Female

Menopausal status:

  • Not specified

Performance status:

  • WHO 0-2

Life expectancy:

  • At least 3 months

Hematopoietic:

  • WBC greater than 4,000/mm^3
  • Absolute granulocyte count greater than 2,000/mm^3
  • Platelet count greater than 100,000/mm^3

Hepatic:

  • Bilirubin no greater than 1.25 times upper limit of normal (ULN)
  • Alkaline phosphatase no greater than 6 times ULN
  • SGOT and/or SGPT no greater than 3 times ULN

Renal:

  • Creatinine no greater than 1.15 times ULN

Cardiovascular:

  • No uncontrolled hypertension
  • No congestive heart failure within the past 6 months
  • No myocardial infarction within the past 6 months

Other:

  • Fertile patients must use effective contraception
  • No acute or chronic infection
  • No second primary tumor
  • No other serious illness

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • No concurrent biologic therapy

Chemotherapy:

  • No prior chemotherapy for metastatic disease
  • Greater than 1 year since prior adjuvant chemotherapy
  • No prior anthracycline or anthraquinone

Endocrine therapy:

  • Hormone resistant disease required of receptor positive patients
  • No concurrent endocrine therapy

Radiotherapy:

  • No prior mediastinal irradiation
  • Adjuvant irradiation of parasternal nodes eligible
  • No prior irradiation to more than 25% of bone marrow
  • No concurrent irradiation of sole measurable lesion

Surgery:

  • Not specified

Other:

  • No concurrent anticoagulant therapy
Female
up to 80 Years
No
Contact information is only displayed when the study is recruiting subjects
Germany
 
NCT00002544
GER-AIO-01/92, CDR0000063279, EU-93011
Not Provided
Not Provided
Arbeitsgemeinschaft fur Internistische Onkologie
Not Provided
Study Chair: Else G. Heidemann, MD Diakonie Klinikum Stuttgart
National Cancer Institute (NCI)
April 2001

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP